Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Share-based Compensation (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Share-based Compensation for 13 consecutive years, with $14.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 29.54% year-over-year to $14.1 million, compared with a TTM value of $52.6 million through Dec 2025, up 22.65%, and an annual FY2025 reading of $52.6 million, up 22.65% over the prior year.
  • Share-based Compensation was $14.1 million for Q4 2025 at Agios Pharmaceuticals, up from $12.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $15.5 million in Q1 2022 and bottomed at $9.1 million in Q3 2023.
  • Average Share-based Compensation over 5 years is $12.1 million, with a median of $11.6 million recorded in 2021.
  • The sharpest move saw Share-based Compensation crashed 34.63% in 2023, then rose 29.54% in 2025.
  • Year by year, Share-based Compensation stood at $11.6 million in 2021, then decreased by 1.34% to $11.5 million in 2022, then increased by 20.49% to $13.8 million in 2023, then dropped by 21.07% to $10.9 million in 2024, then increased by 29.54% to $14.1 million in 2025.
  • Business Quant data shows Share-based Compensation for AGIO at $14.1 million in Q4 2025, $12.4 million in Q3 2025, and $14.7 million in Q2 2025.